Chronic Actinic Dermatitis
Chronic actinic dermatitis (CAD), which used to cover the entities known as actinic reticuloid, photosensitive eczema and persistent light reaction, is the most severe chronic photosensitive skin disorder. It causes persistent eczema with thickened, lichenified skin on sun-exposed areas that can spread to the whole body (erythroderma), along with a sharp drop in the minimal erythema dose (MED) for UVB, UVA and sometimes even visible light.
CAD is driven by a delayed, T cell–mediated (type IV) hypersensitivity reaction against the body's own antigens after they have been altered by light. Crucially, many patients with CAD also have allergic contact dermatitis or photocontact dermatitis to environmental substances (Compositae plants, plant resins, fragrances, sunscreen filters).
- Marked Reduction of MED: In CAD, the UVB and UVA MEDs drop dramatically: around one-tenth of a normal exposure, or even less, is enough to trigger redness and blistering.
- Progression to a Pseudolymphoma Picture (Actinic Reticuloid): In severe chronic disease, constant immune stimulation produces a dense infiltrate of CD8+ T cells in the upper dermis. These T cells develop atypical, cerebriform nuclei, creating a microscopic picture that can be very hard to tell apart from cutaneous T-cell lymphoma (CTCL) / mycosis fungoides.
- Histopathology:
- Epidermis: Acanthosis, hyperkeratosis and parakeratosis, and mild to marked eczematous spongiosis.
- Dermis: A band-like lymphocytic infiltrate in the upper dermis with macrophages, mast cells and occasional eosinophils. Atypical T-cell mitoses may be seen, but there is no malignant monoclonal population (T-cell receptor clonality is negative).
CAD is one of the hardest skin conditions to manage, because patients react to almost the entire solar spectrum and often have overlapping contact allergies. At Haute-Derma, full MED phototesting together with patch and photopatch testing against an environmental allergen series is a required step to pin down the triggers before we start any systemic immunosuppressive treatment.
Clinical Features, Phototesting and Subtypes
The condition mainly affects older men (over 50), often with a history of outdoor work or long-standing contact dermatitis.
How the Disease Progresses
- Sun-exposed skin: It begins on the face and neck (typically sparing the area under the chin and behind the ears), the V of the chest, the backs of the hands and the forearms. The skin becomes red and swollen, with eczematous papules and blisters.
- Spread to covered skin: As the disease becomes chronic, it spreads to skin covered by clothing, because the MED is so low that scattered or reflected light is still enough to trigger a reaction.
- Leonine facies (facies leonina): The facial skin becomes fibrotic, deeply furrowed, rough and thick, resembling leprosy (Hansen's disease) or lymphoma.
- Light-induced erythroderma (actinic erythroderma): The rash covers more than 90% of body surface area (BSA), disturbing temperature control and causing dehydration and exhaustion.
Phototesting and Photopatch Testing
- Phototesting (MED measurement):
- UVB MED: Very low (redness appears at doses below 10–20 mJ/cm²).
- UVA MED: Markedly reduced (reaction at doses below 1–5 J/cm²).
- Visible light: Some patients react even to visible light (400–700 nm).
- Photopatch testing: Identifies triggering allergens such as sesquiterpene lactones (found in the Compositae daisy family), 6-methylcoumarin, fragrance mix, or chemical sunscreen filters (oxybenzone, octocrylene).
How Chronic Actinic Dermatitis Differs From Other Photosensitive Disorders
| Chronic Actinic Dermatitis (CAD) | Polymorphous Light Eruption (PMLE) | Actinic Prurigo (AP) |
|---|---|---|
| Older men (> 50 years) | Young women (20–40 years) | Children (< 10 years) |
| Lichenified, fibrotic eczematous plaques | Papules and vesicles that clear quickly | Fibrotic, excoriated papules; cheilitis |
| Markedly reduced MED (UVB, UVA, visible) | Normal or slightly reduced | Normal or slightly reduced to UVA |
| POSITIVE (+) to multiple allergens | Negative (−) | Negative (−) |
| Pseudolymphoma, POLYCLONAL TCR | Upper dermal edema | Dermal lymphoid follicles |
Diagnosis, Allergen Control and Treatment at Haute-Derma
At Haute-Derma, patients with CAD are managed under our dedicated photosensitivity diagnosis and control pathway (Haute-Derma CAD Protocol):
Skin Biopsy and T-Cell Receptor (TCR) Testing
- H&E and immunohistochemistry: Staining for CD3, CD4, CD8, CD20 and Ki-67 characterizes the T-cell infiltrate in the dermis.
- T-cell receptor gene rearrangement (TCR): A PCR-based molecular test is required to show that the infiltrating T cells are polyclonal, helping rule out the monoclonal pattern of T-cell lymphoma (mycosis fungoides).
Identifying Allergens and Strict Light Avoidance
- Allergen avoidance: Based on photopatch results, patients need to avoid Compositae herbal products, fragranced cosmetics, soaps containing plant-based antiseptics and chemical sunscreens that can cause photoallergy.
- Specialized light protection: Because the MED is so low, patients should stay in rooms with UV-blocking curtains, replace all fluorescent tubes with UV-free LED bulbs, and use fragrance-free mineral sunscreens containing micronized titanium dioxide or zinc oxide.
Standard Systemic Immunosuppression
- TPMT (thiopurine methyltransferase) screening: TPMT activity must be measured before starting azathioprine to avoid acute bone marrow suppression.
- Azathioprine (first-line therapy): Gradually raises the patient's MED over 1–3 months of treatment, allowing them to tolerate ordinary everyday light.
- Cyclosporine A: Used short term during acute flares or erythroderma to quickly shut down T-cell inflammation.
- Mycophenolate mofetil (MMF): A suitable alternative when azathioprine is contraindicated or not tolerated.
Newer Biologics
- Dupilumab (IL-4R alpha blocker): Given as a subcutaneous injection every 2 weeks. Published reports show good results in patients with chronic, fibrotic eczematous CAD that has not responded to conventional immunosuppressants.
